Share this article
Share this article
USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU
Co-Development of Vaccines for Cervical Cancer and HPV
Right of First Refusal for US Marketing of Papilocare™
VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)
( BioVaxys ), the world leader in haptenized protein vaccines for antiviral and cancer applications, and Procare Health Iberia, S.L., of Barcelona, Spain ( Procare Health ), a leading privately-held European pharmaceutical company, announced today that they have entered into a broad collaboration for the co-development, joint commercialization, and marketing of BioVaxys vaccines for ovarian cancer, cervical cancer, and human papilloma virus ( HPV ), and the right of first refusal for marketing by BioVaxys in the United States of Procare Health s vaginal gel product, Papilocare
Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy
Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy Glenmede Investment Management LP (GIM), a privately owned, independent asset management firm, recently celebrated the five-year anniversary of its Glenmede Women in Leadership US Equity Strategy (Strategy). With more than $25.6 million in assets under management as of September 30, 2020, the strategy is a portfolio of large cap stocks, constructed with proprietary multi-factor models, based on a universe of securities with women in various positions of leadership. The strategys investment universe consists of equities of companies which meet an identified percentage of gender diversity in senior management and board membership. Since its inception in December 2015, Glenmedes Women in Leadership U.S. Equity Strategy increased its requirements by 5%. Currently, the strategy re
Features Observation Of Neutralizing Antibodies To SARS-CoV-2
Advancement Of Viral Vaccine Platform And T-cell Diagnostic To Address Emerging SARS-CoV-2 Strains
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)
( BioVaxys or Company ) is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in the European Union ( EU ) for Stage III & Stage IV ovarian cancer, followed by submitting an IND in the US. BioVaxys is in discussions with its designated Contract Manufacturing Organization ( CMO ) and anticipates the execution of a manufacturing contract in 1Q21. The Company plans to submit its Clinical Trial Application ( CTA ) for BVX-0918A with the European Medicines Agenc
Vancouver, BC – January 25, 2021 –
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in the European Union (“EU”) for Stage III & Stage IV ovarian cancer, followed by submitting an IND in the US. BioVaxys is in discussions with its designated Contract Manufacturing Organization (“CMO”) and anticipates the execution of a manufacturing contract in 1Q21. The Company plans to submit its Clinical Trial Application (“CTA”) for BVX-0918A with the European Medicines Agency (“EMEA”) later this year.
Press Release – Chatham Rock Phosphate WELLINGTON New Zealand Chatham Rock Phosphate Limited (TSXV: NZP and NZX: CRP or the Company”) wishes to advise with great pleasure we have successfully concluded negotiations to acquire French Polynesia-based Avenir Makatea Pty Limited. …
WELLINGTON New Zealand – Chatham Rock Phosphate Limited (TSXV: “NZP” and NZX: “CRP” or the “Company”) wishes to advise with great pleasure we have successfully concluded negotiations to acquire French Polynesia-based Avenir Makatea Pty Limited.
The merger of these New Zealand and French Polynesian companies was negotiated at arm’s length and will result in the formation of a new environmentally and culturally sound phosphate company.